ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Activity Overview

This educational activity is an archive of the live presentation held on May 31, 2026.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers involved in the treatment and management of lung, breast, genitourinary, and gynecologic cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate clinical trial data for approved and investigational antibody-drug conjugates (ADCs) and bispecific antibodies across lung, breast, endometrial, and prostate cancers
• Compare mechanisms of action, target biology, and payload platforms across ADC and bispecific antibody classes to inform cross-tumor treatment decisions
• Develop biomarker-informed treatment selection and sequencing strategies for ADCs and bispecifics, integrating patient-specific factors and available evidence
• Anticipate shared and class-specific toxicities of ADCs and bispecific antibodies to guide monitoring and management across clinical settings